Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: Implications for therapeutic drug monitoring

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 3, 2011, Pages 656-663

  De Winter, Brenda C M ^a   Mathot, Ron A A ^a   Sombogaard, Ferdi ^a   Vulto, Arnold G ^a   Van Gelder, Teun ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HYDROLYSIS; DRUG MONITORING; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; RETROSPECTIVE STUDY; VALIDATION STUDY;

ADULT; AGED; BIOLOGICAL AVAILABILITY; CYCLOSPORINE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; NONLINEAR DYNAMICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TACROLIMUS; YOUNG ADULT;

EID: 79953018007     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05440610     Document Type: Article

References (27)

1. van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, Hene RJ, Verpooten GA, Navarro MT, Hale MD, Nicholls AJ: A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 68: 261-266, 1999 (Pubitemid 29360288)
2. van Gelder T, Shaw LM: The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 80[2 Suppl]: S244-S253, 2005
3. de Winter BC, Mathot RA, van Hest RM, van Gelder T: Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome? Expert Opin Drug Metab Toxicol 3: 251-261, 2007
4. Le Meur Y, Buchler M, Thierry A, Caillard S, Villemain F, Lavaud S, Etienne I, Westeel PF, de Ligny BH, Rostaing L, Thervet E, Szelag JC, Rerolle JP, Rousseau A, Touchard G, Marquet P: Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 7: 2496-2503, 2007 (Pubitemid 47566324)
5. Rousseau A, Laroche ML, Venisse N, Loichot-Roselmac C, Turcant A, Hoizey G, Compagnon P, Hary L, Debruyne D, Saivin S, Jacqz-Aigrain E, Buchler M, Villeneuve C, Vergnenegre A, Le Meur Y, Marquet P: Cost-effectiveness analysis of individualized mycophenolate mofetil dosing in kidney transplant patients in the APOMYGRE trial. Transplantation 89: 1255-1262, 2010
6. Kuypers DR, Le Meur Y, Cantarovich M, Tredger MJ, Tett SE, Cattaneo D, Tonshoff B, Holt DW, Chapman J, Gelder T: Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 5: 341-358, 2010
7. West-Thielke P, Kaplan B: Therapeutic monitoring of mycophenolic acid: Is there clinical utility? Am J Transplant 7: 2441-2442, 2007
8. van Hest R, van Gelder T, Bouw R, Goggin T, Gordon R, Mamelok R, Mathot R: Time-dependent clearance of mycophenolic acid in renal transplant recipients. Br J Clin Pharmacol 63: 741-752, 2007 (Pubitemid 46753575)
9. van Hest RM, Mathot RA, Pescovitz MD, Gordon R, Mamelok RD, van Gelder T: Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: A population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 17: 871-880, 2006
10. Sollinger HW, Deierhoi MH, Belzer FO, Diethelm AG, Kauffman RS: RS-61443-a phase I clinical trial and pilot rescue study. Transplantation 53: 428-432, 1992
11. Sombogaard F, Peeters AMA, Baan CC, Mathot RA, Quaedackers M, Vulto AG, Weimar W, Van Gelder T: Inosine monophosphate dehydrogenase messenger RNA expression is correlated to clinical outcomes in mycophenolate mofetiltreated kidney transplant patients, whereas inosine monophosphate dehydrogenase activity is not. Ther Drug Monit 31: 549-556, 2009
12. Sombogaard F, van Schaik RH, Mathot RA, Budde K, van der Werf M, Vulto AG, Weimar W, Glander P, Essioux L, van Gelder T: Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T>C polymorphism. Pharmacogenet Genomics 19: 626-634, 2009
13. de Winter BC, Neumann I, van Hest RM, van Gelder T, Mathot RA: Limited sampling strategies for therapeutic drug monitoring of mycophenolate mofetil therapy in patients with autoimmune disease. Ther Drug Monit 31: 382-390, 2009
14. Wahlby U, Jonsson EN, Karlsson MO: Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci 4: E27, 2002
15. Jonsson EN, Karlsson MO: Xpose: An S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58: 51-64, 1999 (Pubitemid 29049052)
16. Ette EI, Williams PJ, Kim YH, Lane JR, Liu MJ, Capparelli EV: Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol 43: 610-623, 2003 (Pubitemid 36613120)
17. van Gelder T, Silva HT, de Fijter JW, Budde K, Kuypers D, Tyden G, Lohmus A, Sommerer C, Hartmann A, Le Meur Y, Oellerich M, Holt DW, Tonshoff B, Keown P, Campbell S, Mamelok RD: Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: The fixed-dose concentration-controlled trial. Transplantation 86: 1043-1051, 2008
18. van Hest RM, van Gelder T, Vulto AG, Mathot RA: Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet 44: 1083-1096, 2005 (Pubitemid 41356393)
19. de Winter BC, van Gelder T, Glander P, Cattaneo D, Tedesco-Silva H, Neumann I, Hilbrands L, van Hest RM, Pescovitz MD, Budde K, Mathot RA: Population pharmacokinetics of mycophenolic acid: A comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. Clin Pharmacokinet 47: 827-838, 2008
20. Shum B, Duffull SB, Taylor PJ, Tett SE: Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. Br J Clin Pharmacol 56: 188-197, 2003 (Pubitemid 36981434)
21. Hesselink DA, van Hest RM, Mathot RA, Bonthuis F, Weimar W, de Bruin RW, van Gelder T: Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 5: 987-994, 2005 (Pubitemid 40571246)
22. Shaw LM, Korecka M, Venkataramanan R, Goldberg L, Bloom R, Brayman KL: Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 3: 534-542, 2003 (Pubitemid 36612836)
23. Glander P, Sommerer C, Arns W, Ariatabar T, Kramer S, Vogel EM, Shipkova M, Fischer W, Zeier M, Budde K: Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients. Clin J Am Soc Nephrol 5: 503-511, 2010
24. Lee WA, Gu L, Miksztal AR, Chu N, Leung K, Nelson PH: Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 7: 161-166, 1990 (Pubitemid 20208068)
25. Bullingham R, Monroe S, Nicholls A, Hale M: Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 36: 315-324, 1996 (Pubitemid 26125953)
26. Jain A, Venkataramanan R, Kwong T, Mohanka R, Orloff M, Abt P, Kashyap R, Tsoulfas G, Mack C, Williamson M, Batzold P, Bozorgzadeh A: Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil. Liver Transpl 13: 791-796, 2007 (Pubitemid 46939433)
27. Jacobson P, Green K, Rogosheske J, Brunstein C, Ebeling B, DeFor T, McGlave P, Weisdorf D: Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. J Clin Pharmacol 47: 6-12, 2007 (Pubitemid 44973992)